Actively Recruiting
Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis: Long Term Predictive Value (IMAGIN-DEAL in MS)
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-12-09
80
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Multiple sclerosis (MS) is a chronic condition affecting the central nervous system, causing inflammatory and demyelinating lesions in the brain and spinal cord. While treatments have improved to reduce inflammation and relapses, preventing or slowing the neurodegenerative aspect that leads to disability remains challenging. This study focuses on understanding the mechanisms behind neurodegeneration in MS and developing reliable imaging biomarkers to evaluate new treatments and accelerate their clinical use. The research involves long-term follow-up of MS patients previously enrolled in MRI and PET-MR studies. Participants will undergo comprehensive neurological exams, medical history reviews, neuropsychological testing, blood sampling for biobanking, and multimodal MRI scans without contrast. The aim is to validate advanced imaging techniques that capture remyelination, inflammation, and tissue damage to predict disease progression and disability worsening. Participants will be assessed using multiple neurological and cognitive tests, including the Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Score (MSFC), and various processing speed and memory tests. MRI scans will measure white matter lesion load and brain atrophy. The study will monitor participants over the long term to determine the predictive value of imaging markers for disease activity and disability, with all procedures designed to gather detailed data on neurodegeneration in MS.
CONDITIONS
Brief Title
Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with multiple sclerosis and previously enrolled in the INFLASEP, FLUMATEP 1-2, or SHADOWTEP studies for 8 years or more
- Adult patient (18 years or older)
- Affiliated with a social security scheme or beneficiary of such a scheme (except Aide Médicale d'Etat)
- Provided informed consent
You will not qualify if you...
- Unable to undergo MRI due to claustrophobia, pacemaker, or intra-ocular foreign body
- Pregnant, breastfeeding, or lacking effective contraception
- Experiencing severe or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac disease, or other chronic neurological diseases
- Unwilling to be informed if MRI shows a significant medical abnormality
- Currently enrolled in another interventional study without physician's approval
- Under legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Ongoing long-term follow-up
Participants previously enrolled in related studies will be followed up long-term with neurological examinations, neuropsychological testing, blood samples, and multimodal MRI.
1 or more visits for neurological exams and MRI
Trial Site Locations
Total: 1 location
1
CIC Neurosciences
Paris, France, 75013
Actively Recruiting
Research Team
B
Bruno Stankoff, MD
F
Fredy Pene, Mr
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here